In the first trial, plerixafor and G-CSF were included as part of a busulfan and fludarabine conditioning regimen for 45 adult patients (34 AML, seven MDS, and four CML) undergoing allogeneic HSCT (NCT00822770) (119). Here, CSF3 is linked to acute myeloid leukemia.